SNGXbenzinga

Soligenix Announces Interim Results From Ongoing Open-Label Investigator-Initiated Study Of HyBryte; Says Following 18 Weeks Of Treatment, 75% Of Patients Achieved 'Treatment Success'

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 14, 2025 by benzinga